Clinicopathological Significance of HO-1 and HO-2 Expression in Medulloblastoma

Abstract:

Heme oxygenase (HO) is the rate-limiting intracellular enzyme of heme catabolism. Overexpressed HO-1 can inhibit the apoptosis of tumor cells and promote tumor growth and metastasis, and (HO-1) has been considereded to play a major role in the pathogenesis of many tumors. Medulloblastomas (MB) are the most common malignant brain tumors in children and constitute 20% of all pediatric brain tumors. However, there is no report about clinicopathological significance of HO-1 and HO-2 expression in medulloblastoma (MB). In the present study, to explore the expression and potential function of HO in MBs, immunohistochemistry was used to examine the HO-1 and HO-2 expression in 41 MBs. The result showed that immunoreactivity of HO-1 was detected in 32 of 41 MBs and HO-2 was detected in 30 of 41 MBs, and their expression level had no significant correlations with the clinical features of the patients and subtypes of MB. In addition, the prognoses were better in those high HO-1 expression and low HO-2 expression cases. Taken together, the expression of HO-1 and HO-2 protein is significantly correlated with tumor growth in MB. The co-ordinated expression of HO-1 and HO-2 may affect the survival of MB patients. These results suggest that HO-1 may be a potential therapeutic target for MB.

• Periodical: Advanced Materials Research (Volumes 881-883)
• Pages: 469-472
• DOI: https://doi.org/10.4028/www.scientific.net/AMR.881-883.469
• Online since: January 2014
• Authors: Li Tang, Li Yu*
• Keywords: Heme Oxygenase, Immunohistochemistry, Medulloblastoma

References

[1] Gurney JG, Smith MA, Bunin GR. National Cancer Institute. 2000; 51-63.

[2] Nuhn P, Künzli BM, Hennig R, et al. Mol Cancer. 2009; 8: 37.

[3] Sass G, Leukel P, Schmitz V, et al. Int J Cancer . 2008; 123: 1269-1277.

[4] Agarwal, A., and Nick, H. S. J Am Soc Nephrol, 2000; 11, 965-973.

[5] Akagi, R., Takahashi, T., and Sassa, S. Contrib Nephrol. 2005; 148, 70-85.

[6] Wagener, F. A., Eggert, A., Boerman, O. C., et al. Blood. 2001; 98, 1802-1811.

[7] F Giangaspero, CG Eberhart, H Haapasalo, et al. IARC Press, Lyon, France, 2007, pp.132-140.

[8] Datta D, Banerjee P, Gasser M, et al. J Biol Chem. 2010; 285(47): 36842-36848.

[9] Philipp Nuhn1, Beat M Künzli1, René Hennig1, et al. Molecular Cancer. 2009; 8: 37.

[10] Yuanying Ding, Yong Z. Zhang, Kazumichi Furuyama1, et al. FEBS Journal. 2006; 5333–5346.